Elucidating the Encapsulation of Short Interfering RNA in PEGylated Cationic Liposomes
- 2 April 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 25 (9) , 4886-4891
- https://doi.org/10.1021/la803973p
Abstract
Short interfering RNA (siRNA) holds great potential for the treatment of hard-to-cure diseases. One of the major challenges to translate siRNA into drugs is its efficient delivery to its site-of-action, namely the cytoplasm of the target cells. Cationic liposomes have been shown to do the trick, but their short circulation lifetime and potential aggregation in blood limit their applicability for intravenous administration. These hurdles might be overcome by attaching poly (ethylene glycol) (PEG) at the surface of the cationic liposomes through the use of PEGylated lipids. However, this paper reveals that the classical mixing of siRNA with preformed PEGylated cationic liposomes, as frequently done to load PEGylated liposomes with siRNA, prevents an efficient encapsulation of the siRNA in the liposomes. We show that only a minor fraction of the siRNA becomes encapsulated in the core of the PEGylated liposomes, whereas a major part of the siRNA becomes bound at the liposome's outer surface. In serum, the surface-bound siRNA is immediately released and becomes degraded by serum nucleases. By contrast, hydrating a lipid film (containing PEGylated and cationic lipids) directly with a concentrated solution of siRNA (so-called HYDRA protocol), instead of mixing the siRNA with preformed PEGylated liposomes, encapsulates almost 50% of the siRNA in the core of the PEGylated liposomes, which is the maximal encapsulation efficiency for this type of complexes. We show that the siRNA encapsulated in the core of the thus obtained "HYDRA siPLexes" remains fully encapsulated upon dispersing the PEGylated liposomes in human serum.Keywords
This publication has 27 references indexed in Scilit:
- Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticlesJournal of Controlled Release, 2008
- Nucleic acid delivery: Where material sciences and bio-sciences meetMaterials Science and Engineering: R: Reports, 2007
- Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytesProceedings of the National Academy of Sciences, 2007
- Opportunities for treating chronic hepatitis B and C virus infection using RNA interferenceJournal of Viral Hepatitis, 2006
- “SMART” Drug Delivery Systems: Double-Targeted pH-Responsive Pharmaceutical NanocarriersBioconjugate Chemistry, 2006
- RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapyGene Therapy, 2006
- Potent and persistent in vivo anti-HBV activity of chemically modified siRNAsNature Biotechnology, 2005
- Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptorsNature Biotechnology, 2005
- Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAsNature, 2004
- Interference of poly(ethylene glycol)–lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitionsBiochemical Journal, 2002